维昇药业-B（股票代码：02561）于2026年6月22日发布公告称，公司当日通过香港联交所场内回购普通股4,800股，占此前已发行股本（不包括库存股）约0.004%，回购价格介乎每股19.80港元至19.81港元，总成交金额约9.50万港元。回购完成后，公司已发行股本为113,761,664股，库存股数量为165,200股。
公告显示，该次股份回购依据2025年6月27日通过的购回授权进行。根据授权，公司可回购总数为11,392,686股，截至目前已累计回购165,200股；占购回授权通过时已发行股本的0.14501%。公司确认已遵守香港联交所证券上市规则及相关法规，并经董事会正式批准执行上述股份购回事宜。
本公告由执行董事卢安邦签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.